HCR Wealth Advisors lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.5% in the second quarter, Holdings Channel.com reports. The fund owned 7,756 shares of the medical research company’s stock after selling 200 shares during the quarter. Thermo Fisher Scientific comprises 0.7% of HCR Wealth Advisors’ holdings, making the stock its 25th largest holding. HCR Wealth Advisors’ holdings in Thermo Fisher Scientific were worth $2,791,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in TMO. Laurel Wealth Advisors LLC grew its holdings in Thermo Fisher Scientific by 104.3% during the 1st quarter. Laurel Wealth Advisors LLC now owns 94 shares of the medical research company’s stock worth $27,000 after acquiring an additional 48 shares during the period. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $28,000. Ballast Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $35,000. Investors Research Corp grew its holdings in shares of Thermo Fisher Scientific by 100.0% in the 2nd quarter. Investors Research Corp now owns 120 shares of the medical research company’s stock valued at $39,000 after buying an additional 60 shares during the period. Finally, Liberty One Investment Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $41,000. 87.51% of the stock is owned by hedge funds and other institutional investors.
Shares of Thermo Fisher Scientific stock traded up $3.39 during trading on Friday, reaching $413.95. The company’s stock had a trading volume of 1,217,905 shares, compared to its average volume of 1,232,426. Thermo Fisher Scientific Inc. has a 52-week low of $250.21 and a 52-week high of $420.99. The company has a market cap of $163.49 billion, a price-to-earnings ratio of 44.80, a PEG ratio of 1.83 and a beta of 1.04. The firm’s 50-day moving average is $373.97 and its two-hundred day moving average is $335.37. The company has a quick ratio of 2.02, a current ratio of 2.62 and a debt-to-equity ratio of 0.69.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Monday, September 14th. This represents a $0.88 annualized dividend and a yield of 0.21%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 7.13%.
Several equities analysts have recently issued reports on TMO shares. Argus boosted their price target on shares of Thermo Fisher Scientific from $370.00 to $450.00 in a report on Monday, July 27th. Citigroup boosted their price target on shares of Thermo Fisher Scientific from $390.00 to $471.00 and gave the company a “buy” rating in a report on Thursday, July 23rd. UBS Group boosted their price target on shares of Thermo Fisher Scientific from $385.00 to $440.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. BTIG Research boosted their price target on shares of Thermo Fisher Scientific from $372.00 to $475.00 and gave the company a “buy” rating in a report on Thursday, July 23rd. Finally, Robert W. Baird upped their target price on shares of Thermo Fisher Scientific from $352.00 to $436.00 in a research note on Thursday, July 23rd. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Thermo Fisher Scientific currently has an average rating of “Buy” and an average target price of $420.50.
In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $348.00, for a total value of $870,000.00. Following the completion of the transaction, the chief financial officer now directly owns 37,989 shares in the company, valued at approximately $13,220,172. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $349.26, for a total transaction of $6,985,200.00. Following the completion of the transaction, the chief executive officer now owns 294,946 shares of the company’s stock, valued at $103,012,839.96. The disclosure for this sale can be found here. Insiders sold a total of 171,031 shares of company stock valued at $67,284,857 over the last 90 days. Company insiders own 0.44% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Further Reading: How analysts view the yield curve
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.